14 completed, 13 unknown, 12 recruiting, 5 active not recruiting. 26 Phase 2, 14 Phase 1, 5 Not applicable, 4 Phase 3, 1 Phase 4.
Follow Metastatic Gastric Cancer: new trials by email Literature Review of Metastatic Gastric Cancer trials Research Report on Metastatic Gastric Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors TJ037130 - Solid Tumor, Metastatic Ovary Cancer | Phase 1 | Recruiting | TJ Biopharma Co., Ltd. | 128 | 2026-08-05 | 2026-10-30 |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer PF-08634404, Chemotherapy, Nivolumab - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer | Phase 2 / Phase 3 | Recruiting | Pfizer | 840 | 2026-05-14 | 2026-10-13 |
| A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. p95HER2.CAR-TECH2Me - Metastatic Gastric Cancer, Metastatic Breast Cancer | Phase 1 | Recruiting | Vall d'Hebron Institute of Oncology | 15 | 2026-04-29 | 2026-05-22 |
| Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in Colombia Fluoropyrimidine Maintenance Therapy, Immune Checkpoint Inhibitor Maintenance, Targeted Therapy Maintenance - Stomach Neoplasms, Gastric Adenocarcinoma | Recruiting | Fundación Santa Fe de Bogota | 150 | 2026-01-01 | 2026-10-02 | |
| Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Iparomlimab and Tuvonralimab (QL1706), SOX Chemotherapy - Gastric Cancer (GC), Gastroesophageal Junction Cancer | Phase 2 | Recruiting | Beijing Friendship Hospital | 32 | 2025-11-04 | 2026-01-06 |
| Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma SHR2554 Tablets, SHR-A1811 Injection, SHR-A1904 Injection - Advanced Gastric Cancer, Metastatic Gastric Cancer | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 351 | 2025-09-05 | 2025-09-10 |
| Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer Cytoreductive Gastrectomy - Metastatic Gastric Cancer, Gastric Cancer | Not applicable | Recruiting | University Medical Center Ho Chi Minh City (UMC) | 250 | 2025-08-01 | 2025-08-27 |
| First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) Disitamab Vedotin, Sintilimab, S-1 - HER2-positive Gastric Cancer, Metastatic Gastric Cancer | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 110 | 2024-10-17 | 2026-09-15 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-10-30 |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors disitamab vedotin, tucatinib - Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 54 | 2024-05-20 | 2026-07-22 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 Tusamitamab ravtansine - Metastatic Lung Cancer, Metastatic Breast Cancer | Phase 2 | Withdrawn | Erasmus Medical Center | 2024-02-16 | 2024-02-28 | |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer AgenT-797, Botensilimab, Balstilimab - Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-02-01 | 2026-05-15 |
| Study of OB-002 in Patients With Refractory Metastatic Cancer OB-002 - Metastatic Cancer, Metastatic Colorectal Cancer | Phase 1 | Withdrawn | Orion Biotechnology Polska Sp. z o.o. | 2024-01-01 | 2025-04-09 | |
| 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study 89Zr-DFO*-trastuzumab PET scan - Breast Cancer, Metastatic Breast Cancer | Not applicable | Completed | Amsterdam UMC, location VUmc | 6 | 2023-06-26 | 2026-05-27 |
| Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer Radiotherapy targeted to the primary lesion, Radiotherapy targeted to the metastatic lesions, Anti-PD-1 monoclonal antibody - Adenocarcinoma, Stomach Neoplasm | Phase 2 | Recruiting | Fudan University | 55 | 2023-01-01 | 2023-11-08 |
| Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), Nivolumab Injection - Metastatic Gastric Cancer | Phase 1 / Phase 2 | Unknown | CNBG-Virogin Biotech (Shanghai) Ltd. | 43 | 2022-11-17 | 2023-08-24 |
| Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer Nivolumab, Capecitabine, Oxaliplatin - Metastatic Gastric Cancer, PD-L1 Gene Amplification | Phase 2 | Unknown | Kidney Cancer Research Bureau | 23 | 2022-06-05 | 2024-01-02 |
| Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma fruquintinib＋toripalimab + SOX - Metastatic Gastric Cancer | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Zhengzhou University | 64 | 2022-06-01 | 2022-08-18 |
| Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy Phycocare, Placebo - Metastatic Gastric Cancer | Not applicable | Completed | Nantes University Hospital | 73 | 2022-04-01 | 2026-06-17 |
Showing 20 of 51. Sign in to see all of them.
Stomach Neoplasms (51) · Breast Neoplasms (10) · Neoplasm Metastasis (8) · Esophageal Neoplasms (5) · Endometrial Neoplasms (4) · Lung Neoplasms (4) · Ovarian Neoplasms (4) · Pancreatic Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Adenocarcinoma (2) · Adenocarcinoma Of Esophagus (2) · Colorectal Neoplasms (2) · Small Cell Lung Carcinoma (2) · Uterine Diseases (2) · Carcinoma, Hepatocellular (1)
Digestive System Diseases (51) · Digestive System Neoplasms (51) · Gastrointestinal Diseases (51) · Gastrointestinal Neoplasms (51) · Neoplasms (51) · Neoplasms by Site (51) · Stomach Diseases (51) · Breast Diseases (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Neoplastic Processes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6)
Capecitabine (8) · Oxaliplatin (8) · Fluorouracil (6) · Trastuzumab (6) · Nivolumab (5) · Paclitaxel (5) · Docetaxel (4) · Cisplatin (3) · Drug Therapy (3) · Leucovorin (3) · atezolizumab (3) · Bevacizumab (2) · Everolimus (2) · Ramucirumab (2) · S 1 (combination) (2)
Fudan University (2) · NiKang Therapeutics, Inc. (2) · AIO-Studien-gGmbH (1) · Amsterdam UMC, location VUmc (1) · Asan Medical Center (1) · Beijing Friendship Hospital (1) · CNBG-Virogin Biotech (Shanghai) Ltd. (1) · Central South University (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Eli Lilly and Company (1) · Erasmus Medical Center (1) · Fox Chase Cancer Center (1) · Fujian Medical University (1) · Fundación Santa Fe de Bogota (1) · Gottfried Maya (1)
China (16) · United States (10) · Italy (6) · South Korea (6) · Taiwan (5) · France (4) · Germany (4) · Netherlands (4) · Spain (3) · Canada (2) · Israel (2) · Japan (2) · United Kingdom (2) · Australia (1) · Austria (1)
Vincenzo Catalano, MD (2) · Alessandro Bertolini, MD (1) · Alexander Stein, Dr. (1) · Andrea Ciarlo, MD (1) · Chunmei Bai, MD (1) · Claudio Graiff, MD (1) · Claudio Verusio, MD (1) · Daniel Keizman, MD (1) · Daniel L Hertz, PharmD, PhD (1) · Daris Ferrari, MD (1) · Debbie Robbrecht, Dr. (1)
PMID 20458043, PMID 24013904, PMID 32218807, PMID 32487035, PMID 33383486, PMID 35737383, PMID 36670495, PMID 40399487
2017 (1), 2023 (1), 2025 (1), U10CA021115 (1)